BBIO Stock Recent News

Primary endpoint met in BridgeBio Pharma, Inc.'s phase 3 ATTRibute-CM study, which used acoramidis for the treatment of patients with transthyretin amyloid cardiomyopathy; NDA filing expected before end of 2023. Results from the phase 3 ATTRibute-CM study were accepted as a late-breaker presentation for the European Society of Cardiology Congress 2023, taking place August 25 to August 28 of 2023. Results from the phase 3 CALIBRATE study, using encaleret for the treatment of patients with autosomal dominant hypocalcemia type 1 [ADH1] are expected by 1st half of 2024.

BridgeBio Pharma Inc shares surged 69% to $30.78 in late-morning trading on Monday after the commercial-stage biopharmaceutical company announced that Acoramidis, its drug development candidate for a rare heart disease, showed significant improvement in patients in a late-stage study. Acoramidis is being developed to treat transthyretin amyloid cardiomyopathy in which abnormal deposits of a protein called amyloid buildup in the heart, and can cause heart failure, Reuters reported.

BridgeBio Pharma Inc (NASDAQ:BBIO) stock is one of the best stocks on Wall Street today, after the pharma name's heart disease drug, acoramidis, met the main goal in a late-stage study.

BridgeBio Pharma (NASDAQ: BBIO ) stock is climbing higher on Monday as investors react to results from a Phase 3 clinical trial. These results come from the company's ATTRibute-CM study of acoramidis in transthyretin amyloid cardiomyopathy (ATTR-CM).

BridgeBio Pharma Inc.'s stock BBIO, +5.26% rocketed 66% in premarket trade Monday, after the company announced positive results in a late-stage trial of a treatment for transthyretin amyloid cardiomyopathy, or ATTR-CM, a buildup of faulty proteins on the heart that can cause heart failure. The Palo Alto, Calif.

BridgeBio Pharma is slated to announce late-stage results for an important pipeline candidate on Monday. Roivant Sciences might be close to a major asset sale that could spark a hefty rally in its shares.

Shares of BridgeBio Pharma Inc. BBIO, -3.29% gained 5.5% premarket on Tuesday after the company announced that its investigational treatment for children with achondroplasia, a bone growth disorder that causes disproportionate short stature, resulted in significant growth in a clinical trial. More than 80% of children in the study responded to the treatment, infigratinib, based on at least a 25% increase in annual height velocity, the company said in a release.

JPMorgan cautioned investors ahead of a key clinical readout for BridgeBio this coming July. As a result, the biotech's stock is falling today.

PALO ALTO, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that the updated six month results from Cohort 5 in PROPEL2, a Phase 2 trial of the investigational therapy, infigratinib in children with achondroplasia will be featured in an oral presentation at the Endocrine Society (ENDO) 2023 Annual Conference, taking place in Chicago, Illinois on June 15 – 18, 2023.

PALO ALTO, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that updated data from CANaspire, its Phase 1/2 clinical trial of BBP-812, an investigational intravenous (IV) adeno-associated virus serotype 9 (AAV9) gene therapy for the treatment of Canavan disease, will be presented at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, taking place in Los Angeles, CA on May 16 – 20, 2023.